146 217

Cited 3 times in

Quantitative coronary angiography versus intravascular ultrasound guidance for drug-eluting stent implantation (GUIDE-DES): study protocol for a randomised controlled non-inferiority trial

Authors
 Pil Hyung Lee  ;  Soon Jun Hong  ;  Hyun-Sook Kim  ;  Young Won Yoon  ;  Jong-Young Lee  ;  Seung-Jin Oh  ;  Soo-Jin Kang  ;  Young-Hak Kim  ;  Seong-Wook Park  ;  Seung-Whan Lee  ;  Cheol Whan Lee 
Citation
 BMJ OPEN, Vol.12(1) : e052215, 2022-01 
Journal Title
BMJ OPEN
Issue Date
2022-01
MeSH
Coronary Angiography / methods ; Coronary Artery Disease* / diagnostic imaging ; Coronary Artery Disease* / surgery ; Drug-Eluting Stents* ; Humans ; Multicenter Studies as Topic ; Percutaneous Coronary Intervention* / methods ; Randomized Controlled Trials as Topic ; Treatment Outcome ; Ultrasonography, Interventional / methods
Keywords
coronary heart disease ; coronary intervention ; ischaemic heart disease
Abstract
Introduction: Angiography remains the gold standard for guiding percutaneous coronary intervention (PCI). However, it is prone to suboptimal stent results due to the visual estimation of coronary measurements. Although the benefit of intravascular ultrasound (IVUS)-guided PCI is becoming increasingly recognised, IVUS is not affordable for many catheterisation laboratories. Thus, a more practical and standardised angiography-based approach is necessary to support stent implantation.

Methods and analysis: The Quantitative Coronary Angiography versus Intravascular Ultrasound Guidance for Drug-Eluting Stent Implantation trial is a randomised, investigator-initiated, multicentre, open-label, non-inferiority trial comparing the quantitative coronary angiography (QCA)-guided PCI strategy with IVUS-guided PCI in all-comer patients with significant coronary artery disease. A novel, standardised, QCA-based PCI protocol for the QCA-guided group will be provided to all participating operators, while the PCI optimisation criteria will be predefined for both strategies. A total of 1528 patients will be randomised to either group at a 1:1 ratio. The primary endpoint is the 12-month cumulative incidence of target-lesion failure defined as a composite of cardiac death, target-vessel myocardial infarction or ischaemia-driven target-lesion revascularisation. Clinical follow-up assessments are scheduled at 1, 6 and 12 months for all patients enrolled in the study.

Ethics and dissemination: Ethics approval for this study was granted by the Institutional Review Board of Asan Medical Center (no. 2017-0060). Informed consent will be obtained from every participant. The study findings will be published in peer-reviewed journal articles and disseminated through public forums and academic conference presentations. Cost-effectiveness and secondary imaging analyses will be shared in secondary papers.

Trial registration number: NCT02978456.
Files in This Item:
T202205154.pdf Download
DOI
10.1136/bmjopen-2021-052215
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Yoon, Young Won(윤영원) ORCID logo https://orcid.org/0000-0002-0907-0350
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/191174
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links